secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001493152-24-006266
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics preclinical data: HDF spheroids cut psoriasis severity 35% in mice
--------------------------------------------------------------------------------

- Presented at 2024 Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases.
- Single IV dose of HDF spheroids reduced average PASI score by 35% (p<0.0001) in IMQ-induced psoriasis mouse model.
- Spheroids also ameliorated IMQ-induced spleen enlargement and normalized lymphocyte and monocyte counts.
- In vitro, HDFs inhibited TNF-α and IL-17 and suppressed dendritic cell maturation via CD40/CD80/CD86 downregulation.
- Company holds 150+ issued/pending patents; data supports IND-enabling studies for early-discovery psoriasis program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224006266/0001493152-24-006266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224006266/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer